Structure therapeutics crunchbase
WebStructure Therapeutics Inc is a clinical-stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. WebStoke’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. We are also pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder.
Structure therapeutics crunchbase
Did you know?
WebStructure Therapeutics has 6 current employee profiles, including Chief Executive Officer & Founder Raymond Stevens. Structure Therapeutics has 4 board members and advisors, including Jessica Lifton. Contacts Job Department Search Contacts... Ashley Elinson Sr. Director, New Product Planning & Corporate Strategy Director 1 phone number found WebStructure Therapeutics has raised a total of $207M in funding over 5 rounds. Their latest funding was raised on Aug 1, 2024 from a Series B round. Structure Therapeutics is …
WebMar 22, 2024 · Flare Therapeutics, a drug discovery startup, announced on Wednesday it raised $123 million in Series B funding. The round was co-led by GordonMD Global … WebStructure’s platform combines the latest advancements in visualization of molecular interactions, computational chemistry and data integration to develop differentiated …
WebA New Class of Therapeutics Foghorn is pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression. These precision therapeutic candidates target disease dependencies within the chromatin regulatory system, which means they change how genes turn on and off. WebCircle Pharma – Structure-Based Design of Bioavailable Macrocycle Therapeutics Structure-Based Design of Bioavailable Macrocycle Therapeutics We are developing macrocycle therapeutics to address “undruggable” targets. Our pipeline is focused in precision oncology. About us A new paradigm for macrocycle drug discovery
WebApr 26, 2010 · Key strengths include: • Market research, conducting due diligence • Ability to communicate with all levels of firm • Problem solver; can turn chaos into structure • Ability to work in a...
WebJan 30, 2024 · Structure Therapeutics IPO Details GPCR intends to sell 8.95 million American Depositary Shares representing underlying common stock at a proposed midpoint price of $14.00 per share for gross... exeter township election resultsWebAug 1, 2024 · SAN FRANCISCO & SHANGHAI, August 01, 2024 -- ( BUSINESS WIRE )--Structure Therapeutics Inc. (Structure Therapeutics), formerly known as ShouTi Inc., today announced it closed an... bthelp.website2.meWebFeb 3, 2024 · Structure Therapeutics is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat chronic metabolic and … exeter township football scoresWebJan 31, 2024 · RANAR Therapeutics General Information. Description. Developer of RNA structure intended to treat cancer. The company targets RNA structures with small … bt help remote codesWebStructure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR. South San Francisco, California, United States 51-100 Series … bt help remoteWebTherapeutic Area Focus. Chronic diseases are rapidly increasing worldwide, escalating the demand for life-changing medicines. These conditions represent 73% of all deaths worldwide and 60% of the global burden of disease. At Structure, we are determined to transform these devastating figures with innovative, small molecule medicines. bt help textWebOrna Therapeutics is leaving linear thinking behind to create fully engineered oRNATM circular RNAs – an entirely new class of RNA medicines that can realize the full potential of RNA and which is poised to change the way we treat disease. exeter township dunn